Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) EBT: 2016-2024

Historic EBT for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to -$43.3 million.

  • Mereo BioPharma Group's EBT rose 53.18% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 9.32%. This contributed to the annual value of -$43.3 million for FY2024, which is 44.19% down from last year.
  • Per Mereo BioPharma Group's latest filing, its EBT stood at -$43.3 million for FY2024, which was down 44.19% from -$30.0 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's EBT ranged from a high of $19.2 million in FY2021 and a low of -$213.7 million during FY2020.
  • Over the past 3 years, Mereo BioPharma Group's median EBT value was -$42.9 million (recorded in 2022), while the average stood at -$38.7 million.
  • Per our database at Business Quant, Mereo BioPharma Group's EBT surged by 108.98% in 2021 and then slumped by 323.67% in 2022.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's EBT stood at -$213.7 million in 2020, then spiked by 108.98% to $19.2 million in 2021, then crashed by 323.67% to -$42.9 million in 2022, then surged by 30.14% to -$30.0 million in 2023, then slumped by 44.19% to -$43.3 million in 2024.